Work

Abstract A088: Novel anti-EGFR antibody-drug conjugate AVID100: A phase 2a trial in patients with EGFR-overexpressing advanced solid tumors

Year: 2019

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-19-a088

Authors: Jason Melear, Nehal Lakhani, Joyce A O'Shaughnessy, Sharon T Wilks, Saad Khan, Sree R Chandana, Anthony W Tolcher, Kyri P Papadopoulos, Yvette Cole, Karla Rivas, Ria Ghosh, Sandra Sinclair, Robert Lutz, Paul I Nadler, Debra L Wood, Barbara Burtness

Institutions: Texas Oncology, The University of Texas Southwestern Medical Center, South Texas Accelerated Research Therapeutics, Yale Cancer Center

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3001273004

Cites:

Cited by: 3

Related to: 10